| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Executive Officer
1 company
William B. Stilley III last filed a Form 4 in May 2023, as Director at ADIL. William B. Stilley III's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 1,261,779 shares of ADIL. Net of sales, the ADIL filings show accumulation of 125,600 shares.
William B. Stilley III has 14 Form 4 filings on record from July 2018 to May 2023, across 2 companies: Director at Adial Pharmaceuticals (ADIL), 2018–2023; Director at Avalon GloboCare (ALBT), 2020–2021.
The 27 reported transactions were 9 option or other derivative awards, 6 open-market purchases, 6 other transactions and 4 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $88K and no sales.
The largest open-market purchase was 20,600 shares of ADIL at an average $2.67 on November 30, 2021, about $55K. Twelve months later ADIL was down 90%.
Shares as reported in the last Form 4 for each company; the most recent is from May 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 30, 2021 | ADIL Adial Pharmaceuticals, Inc. | Chief Executive Officer | Buy | 20,600 | $2.67 | $55,070.62 | +2.2% | -25.9% | -90.3% | |
| Mar 26, 2020 | ADIL Adial Pharmaceuticals, Inc. | Chief Executive Officer | Buy | 25,000 | $1.30 | $32,551.68 | +3.6% | - | - | |
| Jul 31, 2018 | ADIL Adial Pharmaceuticals, Inc. | Chief Executive Officer | Buy | 80,000 | $0.00 | - | +18.9% | - | - |